Abrdn PLC Alnylam Pharmaceuticals, Inc. Transaction History

Abrdn PLC

$51.7 Billion
Q4 2024

A detailed history of Abrdn PLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Abrdn PLC holds 190,841 shares of ALNY stock, worth $51.8 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

190,841

Previous 200,069 4.61%

Holding current value

$51.8 Million

Previous $55 Million 18.4%

% of portfolio

0.09%

Previous 0.1%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 24, 2025	SELL	$232.27 - $300.43 $2.14 Million - $2.77 Million	-9,228 Reduced 4.61%	190,841 $44.9 Million
Q3 2024 Oct 24, 2024	BUY	$233.81 - $287.01 $21,276 - $26,117	91 Added 0.05%	200,069 $55 Million
Q2 2024 Aug 09, 2024	SELL	$143.31 - $247.0 $2.77 Million - $4.77 Million	-19,297 Reduced 8.8%	199,978 $48.6 Million
Q1 2024 May 08, 2024	SELL	$146.51 - $198.2 $1.97 Million - $2.66 Million	-13,441 Reduced 5.78%	219,275 $32.8 Million
Q4 2023 Jan 31, 2024	BUY	$151.41 - $196.57 $31.7 Million - $41.2 Million	209,691 Added 910.71%	232,716 $44.5 Million
Q3 2023 Nov 06, 2023	SELL	$170.77 - $211.65 $95,460 - $118,312	-559 Reduced 2.37%	23,025 $4.08 Million
Q2 2023 Jun 20, 2024	BUY	$185.01 - $212.05 $24,051 - $27,566	130 Added 0.55%	23,584 $4.48 Million
Q2 2023 Aug 04, 2023	BUY	$185.01 - $212.05 $24,051 - $27,566	130 Added 0.55%	23,584 $4.48 Million
Q1 2023 Jun 20, 2024	BUY	$182.66 - $235.53 $1.89 Million - $2.43 Million	10,330 Added 78.71%	23,454 $4.7 Million
Q1 2023 Apr 28, 2023	BUY	$182.66 - $235.53 $1.89 Million - $2.43 Million	10,330 Added 78.71%	23,454 $4.7 Million
Q4 2022 Jun 20, 2024	SELL	$185.53 - $241.31 $38.2 Million - $49.7 Million	-206,151 Reduced 94.01%	13,124 $3.12 Million
Q4 2022 Feb 09, 2023	BUY	$185.53 - $241.31 $169,759 - $220,798	915 Added 7.49%	13,124 $3.12 Million
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $195,064 - $326,656	1,408 Added 13.04%	12,209 $2.44 Million
Q2 2022 Aug 05, 2022	SELL	$120.42 - $169.29 $26,733 - $37,582	-222 Reduced 2.01%	10,801 $1.58 Million
Q1 2022 May 04, 2022	SELL	$127.18 - $173.91 $18,313 - $25,043	-144 Reduced 1.29%	11,023 $1.81 Million
Q4 2021 Feb 08, 2022	BUY	$159.56 - $209.29 $60,951 - $79,948	382 Added 3.54%	11,167 $1.89 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $115,939 - $141,879	683 Added 6.76%	10,785 $2.04 Million
Q2 2021 Aug 10, 2021	SELL	$128.63 - $176.89 $262,791 - $361,386	-2,043 Reduced 16.82%	10,102 $1.71 Million
Q1 2021 May 06, 2021	BUY	$126.83 - $175.69 $32,975 - $45,679	260 Added 2.19%	12,145 $1.72 Million
Q4 2020 Feb 10, 2021	BUY	$122.97 - $147.0 $19,552 - $23,373	159 Added 1.36%	11,885 $1.55 Million
Q3 2020 Oct 21, 2020	SELL	$121.19 - $165.49 $365,509 - $499,117	-3,016 Reduced 20.46%	11,726 $1.71 Million
Q2 2020 Aug 10, 2020	BUY	$104.21 - $156.44 $37,828 - $56,787	363 Added 2.52%	14,742 $2.18 Million
Q1 2020 May 13, 2020	SELL	$93.12 - $133.99 $13,223 - $19,026	-142 Reduced 0.98%	14,379 $1.57 Million
Q4 2019 Feb 18, 2020	BUY	$74.51 - $124.23 $83,898 - $139,882	1,126 Added 8.41%	14,521 $1.67 Million
Q3 2019 Nov 13, 2019	BUY	$70.9 - $87.82 $37,789 - $46,808	533 Added 4.14%	13,395 $1.08 Million
Q2 2019 Aug 13, 2019	BUY	$65.86 - $92.79 $84,037 - $118,400	1,276 Added 11.01%	12,862 $933,000
Q1 2019 May 14, 2019	BUY	$72.76 - $93.45 $494,258 - $634,805	6,793 Added 141.73%	11,586 $1.08 Million
Q4 2018 Feb 12, 2019	SELL	$62.67 - $88.33 $3,133 - $4,416	-50 Reduced 1.03%	4,793 $329,000
Q3 2018 Nov 13, 2018	SELL	$87.52 - $122.67 $9,627 - $13,493	-110 Reduced 2.22%	4,843 $424,000
Q2 2018 Aug 09, 2018	BUY	$88.31 - $107.8 $437,399 - $533,933	4,953 New	4,953 $488,000

Others Institutions Holding ALNY

# of Institutions

650

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.23M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.4B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.

Account